Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: """We're No. 23"" may not sound like a stirring claim, but Gov. John Kasich has been using one version of it to lead cheers for Ohio. ""We jumped 11 spaces since beginning this year in terms of being job-friendly,"" he said in an interview July 12, 2011, with former Fox News colleague Sean Hannity, crediting the improvement to ""probably the most massive comprehensive piece of legislation passed in modern times in Ohio."" He was referring to the recently passed state budget, which he signed into law June 30. He cited more accomplishments and some sources of information when he repeated the claim the next day with former House colleague Joe Scarborough and Mika Brzezinski on MSNBC: ""My state was dying. It is my job to get us out of this. We jumped, according to CNBC, 11 places since I've become governor as business friendly in America."" And Kasich got a third chance to tout Ohio July 17, 2001, on NBC's ""Meet the Press,"" telling host David Gregory: ""Ohio was dying, and we are beginning to really become business-friendly. ... In Ohio, because we faced our $8 billion budget deficit and provide tax relief, what's happened? CNBC says we've jumped 11 points, 11 places in terms of business-friendly."" PolitiFact Ohio decided to take a look at the claim. The governor’s office confirmed he was talking about CNBC's annual rating of ""America's top states for business,"" which the business channel released in June. Ohio ranked 23rd. That is, in fact, an advance of 11 spots from last year’s list, which made Ohio the most improved state (followed by Florida and Pennsylvania). CNBC said its study used input from business groups including the National Association of Manufacturers and the Council on Competitiveness to rank states in 10 categories: cost of doing business; workforce; quality of life; economy; transportation and infrastructure; technology and innovation; education; business friendliness; access to capital, and cost of living. Ohio's biggest improvement came in the ""cost of doing business"" category, based on tax burden, including individual income and property taxes, and business taxes, particularly as they apply to new investments. Utilities, wages and rental space were also figured. That specific improvement was hailed by the Ohio Business Development Coalition, which said, ""Ohio improved to 5th place from 29th place last year due to a multi-year effort to reform the state's tax structure, which took full effect in 2010."" In April, the coalition noted, a report from Ernst & Young with the Council On State Taxation ranked Ohio as having the third friendliest tax environment in the nation. Those tax reforms came before Kasich's watch, however; they started two administrations ago, under Republican Gov. Bob Taft and a GOP-controlled legislature in 2005. Kasich can claim some credit in the category of economy, where the study measured each state’s fiscal health by looking at projected budget gaps or surpluses for the coming fiscal year. Ohio moved up 10 spots to 24th. We think it's fair to allow the governor some license for salesmanship, but we don't think it's splitting hairs to note that the CNBC study did not give Ohio high marks for being ""job friendly"" or ""business friendly"" as he stated. His underlying meaning is that Ohio’s business climate has improved, and his wording is similar to the name of the study, ""America’s top states for business."" But Ohio did not fare as well in some of the study’s 10 categories as it did overall. One category specifically graded states ""on the perceived 'friendliness' of their legal and regulatory frameworks to business."" Ohio ranked 42nd in it. The state was dead last in the ""workforce"" category. CNBC says states were rated ""on the education level of their workforce, as well as the numbers of available workers. We also considered union membership. While organized labor contends that a union workforce is a quality workforce, that argument, more often than not, doesn’t resonate with business. We also looked at the relative success of each state’s worker training programs in placing their participants in jobs."" CNBC's list is one of many. Chief Executive magazine annually rates the ""best/worst states for business,"" using input on ""overall business-friendliness"" from 550 CEOs. Ohio this year ranked 41st -- improved two places from last year but down 19 places from 2006, making the state one of the biggest losers over five years (with Illinois, Washington, Maryland and Pennsylvania). The conservative-leaning Tax Foundation ranked Ohio 46th in its state business tax rankings for 2011. But the Small Business and Entrepreneurship Council, a trade group that represents small businesses and advocates for less government regulation, annually issues a rigorous ""Business Tax Index"" that pulls together 18 different tax measures to rank the states from best to worst in terms of the costs of their tax systems on entrepreneurship and small business. The index for 2011, published in April, ranked Ohio 9th. The SBE Council also has a ""Small Business Survival Index"" that evaluates states in 36 categories including  corporate and income taxes, gas and diesel taxes, government spending, health care and energy costs, inheritance taxes, and workers compensation costs. The latest, released in December, rated Ohio 9th in the nation, up from 11th a year earlier. So where does that leave the governor’s claim? He was correct that Ohio jumped 11 places in a study from CNBC, although he misstated the name of the study. The state didn’t fare as well in some catagories of that study, including one that specifically looked at perceived friendliness to business. There also are several other rankings for business climate and tax burdens out there. In some of those, Ohio has shown improvement. Others, however, still have the state low in their rankings. And some of the tax changes that boosted the state were put in place by previous administrations. Kasich was trying to show progress in Ohio, selling both the state and his stewardship. In his claim, he was citing only one study. On that study his statement was accurate, but these other points help clarify the picture. On the Truth-O-Meter, that gets a rating of ."

Output: We jumped 11 places since beginning this year in terms of being job-friendly.


Input: Consider Input: Bayer acquired Monsanto this year for $63 billion. “If we can settle nuisances at some point where the defense costs in preparing cases are higher than potential settlement amounts, we will of course consider it from an economic standpoint,” CEO Werner Baumann told reporters when asked whether there was any scenario in which Bayer would consider settling. He added: “We will resolutely and with all means defend ourselves in this (glyphosate) litigation.”  Baumann was speaking on Monday to German media invited to visit Bayer’s new operations in the former research and development facilities of Monsanto in St. Louis, Missouri. The remarks, made on Monday, were embargoed to the end of the week to allow media to return home. Shares in Bayer have lost 25 percent in value since Aug. 10, when a San Francisco jury awarded $289 million to Dewayne Johnson on grounds Monsanto failed to warn the school groundskeeper and other consumers of the cancer risks posed by glyphosate-based RoundUp and Ranger Pro. Johnson has terminal non-Hodgkin’s lymphoma that he alleges was caused by the herbicides. A judge later reduced the award to $78 million. Bayer denies that glyphosate causes cancer and says decades of scientific studies and real-world use have shown the chemical to be safe for human use. The company is appealing the findings. The number of glyphosate cases that Bayer faces across the United States has jumped to more than 8,700, prompting concerns among investors about the impact of litigation costs on Bayer’s bottom line. Baumann expressed confidence that Bayer could handle the litigation, and cited its “inexpensive” $12 million settlement of 4,000 lawsuits over its contraceptive Mirena device. Bayer also won five of six trials over its best-selling bloodthinner Xarelto, over which it faces 24,000 U.S. lawsuits. The sixth jury found in favor of a plaintiff, but a judge later overturned the decision. “Due to our exposure as a pharmaceutical company, we have the experience to defend those (glyphosate) cases,” he said. Baumann said the company’s legal strategy had been revised following the integration of Bayer and Monsanto in mid-August. He declined to provide details, but recent court filings reveal some of the steps the company has taken. Last week, Bayer added the attorneys from law firm Arnold & Portner who won the Xarelto cases for the company to its glyphosate defense team. It is also trying to change the juror selection process for upcoming trials. In filings last week in San Francisco federal court, where a new glyphosate trial is scheduled to begin on Feb. 25, 2019, Bayer said the “jury pool likely has grown more hostile” due to negative media coverage following the Johnson verdict. Michael Miller, one of the attorneys for the plaintiff, said the company’s claims were “hypocritical beyond belief” given its own efforts to control the message on glyphosate, most recently in a full-page advertisement in the Washington Post. Bayer has asked U.S. District Judge Vince Chhabria, who is overseeing the San Francisco case and some 580 others, to significantly expand the jury pool and question prospective jurors about their knowledge of the media coverage of the cases. Chhabria is expected to decide on the requests in December.

Output: Bayer CEO says would consider glyphosate settlement depending on costs.


Input: Consider Input: This release makes no mention of the costs of the drugs compared in this study, even though the drugs have been in use for years and are widely available. Since the study is a comparison of various treatments for this form of cancer, it seems relevant to offer a cost comparison as well as a comparison of efficacy. It appears that the high dose methotrexate is given over a 24-hour period, presumably in the hospital, while the standard methotrexate is given as a single dose. Also, the high dose methotrexate is followed by leucovorin administration while the standard dose is not. According to the site GoodRx, the cost for methotrexate in low-dose (2.5 mg) pill form averages out to about $50 for a month’s supply. Newer, injectable variations of the drug cost upwards of $500 a month for the 25 mg dose. The release states that patients receiving high doses of the drug methotrexate “had a significantly better outcome, by 5 to 6 percent” than did patients receiving the current standard of care, which is gradually escalating doses of the drug. The release also explains that patients nine years old or younger who were also treated with a steroid called decadron (dexamethasone) for half as long as normal (14 versus 28 days) benefited from the treatment while patients 10 and older did not. We’re not sure of the meaning behind these results as portrayed in the release. Which outcome was better by 5 or 6 percent? The study has several. Does that mean the relapse rate was reduced or is it the event free survival that was better? It would be more meaningful to readers if the release had included the actual relapse and event free survival rates for each group analyzed in terms most people can understand. For example: “relapse rates were 5 percent lower in Group X compared to Group Y.” We’ll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone “were at much higher risk for a debilitating bone condition called osteonecrosis,” although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well. The release stated the study was randomized and controlled, and provides a broad overview of the study design, for which we give the release a borderline satisfactory under this criteria. However, these are the superficial results. On deeper delving into the study methodology, the statistical significances of the results were very close to not statistically significant. This is due to their planned interim stopping of the treatment and the fact that they were looking at multiple outcomes in multiple groups. This release doesn’t demonstrate disease-mongering. While the release does say that this clinical trial was run by the Children’s Oncology Group, which is funded by the National Cancer Institute and the National Institutes of Health, it makes no mention of possible conflicts of interest. Compounding that is the fact that the published study says, “Disclosures provided by the authors are available with this article at www.jco.org,” but that information is behind the journal’s paywall for most readers, so it’s unknown if there is, or is not, a conflict. It appears as though five of the authors (out of a total of about 20) have some conflicts of interest, mostly from several types of drug company payments. The release is comparing the efficacy of treatment regimens using different drugs so alternative treatments for B-acute lymphoblastic leukemia are noted. The release makes clear at the end that the treatment of this disease is improving thanks to refinement of the use of existing drug treatments, meaning that they are readily available for patient use. The release suggests the study findings could change the way childhood leukemia is treated. Modifying existing treatments to enhance a patient’s survival is certainly novel enough to warrant a release. There is no use of unjustifiable language in this release. However, the tone may be a bit overly optimistic given the study findings.


Output: Relapses of childhood leukemia improve with high doses of common chemo drug